NCT02682823 - Tocilizumab Real-Life Human Factors (RLHFs) Validation Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

July 29, 2016

Study Completion Date

July 29, 2016

Conditions

Rheumatoid Arthritis

Interventions

DEVICE

AI-1000 G2

Tocilizumab will be administered using the AI-1000 G2.

DRUG

Tocilizumab

Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.

Trial Locations (8)

15090

Advanced Rheumatology & Arthritis Research Center, Wexford

16635

Altoona Center For Clinical Research, Duncansville

40515

Bluegrass Comm Research, Inc., Lexington

74104

Oklahoma Center For Arthritis Therapy & Research, Tulsa

75231

Metroplex Clinical Research, Dallas

85202

Arizona Arthritis and Rheuma, Mesa

90720

Valerius Medical Group & Research Ctr of Greater Long Beach, Los Alamitos

93454

Pacific Arthritis Ctr Med Grp, Santa Maria

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY